LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

1.99 -2.93

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.96

Max

2.05

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+335.5% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-45M 742M
Ouverture précédente	4.92
Clôture précédente	1.99

Sentiment de l'Actualité

By Acuity

50%

154 / 344 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juin 2026, 23:22 UTC

Résultats

Principaux Mouvements du Marché

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 juin 2026, 23:09 UTC

Actions en Tendance

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 juin 2026, 20:51 UTC

Résultats

Costco Reports 15% Sales Growth in May

3 juin 2026, 20:43 UTC

Résultats

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 juin 2026, 23:48 UTC

Market Talk

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 juin 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 juin 2026, 23:35 UTC

Market Talk

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 juin 2026, 23:15 UTC

Market Talk

Résultats

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 juin 2026, 22:08 UTC

Actions en Tendance

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 juin 2026, 21:54 UTC

Market Talk

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 juin 2026, 21:18 UTC

Résultats

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 juin 2026, 21:15 UTC

Résultats

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 juin 2026, 21:13 UTC

Résultats

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 juin 2026, 21:13 UTC

Résultats

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 juin 2026, 21:12 UTC

Résultats

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 juin 2026, 21:09 UTC

Résultats

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 juin 2026, 21:03 UTC

Résultats

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 juin 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 juin 2026, 20:43 UTC

Résultats

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 juin 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 juin 2026, 20:37 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 juin 2026, 20:35 UTC

Résultats

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 juin 2026, 20:17 UTC

Résultats

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 juin 2026, 20:17 UTC

Résultats

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 juin 2026, 20:15 UTC

Acquisitions, Fusions, Rachats

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Adj EPS $2.44 >AVGO

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q EPS $1.91 >AVGO

3 juin 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

3 juin 2026, 20:15 UTC

Résultats

Broadcom 2Q Rev $22.19B >AVGO

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

335.5% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 335.5%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

154 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.